MENARINI is a fully integrated privately owned pharma company with a long and successful heritage in strategic partnering across the globe. We have a profound know-how stemming from our strong R&D capabilities in key therapeutic areas, coupled with our excellence in commercial execution and our powerful direct presence on a global basis.
The Global Challenge of Antimicrobial resistance (AMR)
Antimicrobial resistance (AMR) represents a global public health threat.
AMR is a dynamic phenomenon, microorganisms evolve leading to loss of susceptibility to antimicrobial drugs. As a result, infections persist and may spread to others.
Over the years, use and misuse of antimicrobials, lack of infection control practises, global travel and trade, have all contributed to the acceleration of AMR. Consequently, an increasing number of infectious diseases are becoming difficult to manage, with dramatic health and economic impact.
Although over the last decade resistant infections have also been seen in the community, multidrug resistant infections are frequently associated with the hospital health-care setting, affecting the most frail patients. With resistance on the rise, we stand to lose the immense ground we have gained in in the medical field over the last century.
(ref. WHO website)
